Breast

We have two main projects on cancer mammae:

CCIS Study
Ductal Carcinoma in situ represents certain challenges in diagnostics, because around 20 % develop into invasive cancer and there are no certain markers to identify these. We have analysed a number of samples using both DNA ploidy and nucleotyping.

Mammae cancer, stadium I
In this case we have a total of 480 patients with a defined prognosis (good prognosis: no relapse > 7 years after treatment. Bad prognosis: relapse or death of cancer within 4 years). The study is a pilot for DNA ploidy and nucleotyping as a prognostic marker in breast cancer. There are also planned to do a comparison of alternative methods for DNA ploidy measurements (FCM, manual ICM, automated ICM) and S-phase calculations.